A custom panel to analyze all exons of PTEN gene was used. Details on target regions of panel are given in
Supplementary Table S3 20 ng of DNA were used for each multiplex PCR amplification. The quality of the obtained libraries was evaluated by the
Agilent 2100 Bioanalyzer on-chip electrophoresis (Agilent Technologies). Emulsion PCR was performed with the
Ion OneTouch™ OT2 System (Life Technologies). Sequencing was run on the Ion Proton (PI, Life Technologies) loaded with Ion PI Chip v2. Data analysis, including alignment to the hg19 human reference genome and variant calling, was done using the Torrent Suite Software v.5.0 (Life Technologies). Filtered variants were annotated using a custom pipeline based on vcflib (
https://github.com/ekg/vcflib), SnpSift1, the Variant Effect Predictor (VEP) software2 and NCBI RefSeq database. A baseline for CNV detection was performed using 10 normal male DNA extracted from fresh frozen tissues. Copy number variation analysis of gene was performed using adequate pipeline using IonReporter 5.0 version (Life Technologies).
Milella M., Falcone I., Conciatori F., Matteoni S., Sacconi A., De Luca T., Bazzichetto C., Corbo V., Simbolo M., Sperduti I., Benfante A., Del Curatolo A., Cesta Incani U., Malusa F., Eramo A., Sette G., Scarpa A., Konopleva M., Andreeff M., McCubrey J.A., Blandino G., Todaro M., Stassi G., De Maria R., Cognetti F., Del Bufalo D, & Ciuffreda L. (2017). PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Scientific Reports, 7, 43013.